1-2 of 2
Amanda Woo
Close
Sort by
Journal Articles

CRISPR/Cas9 Genome Editing to Treat Sickle Cell Disease and B-Thalassemia: Re-Creating Genetic Variants to Upregulate Fetal Hemoglobin Appear Well-Tolerated, Effective and Durable.

Michelle I. Lin, PhD, Elizabeth Paik, PhD, Bibhu Mishra, PhD, David Burkhardt, Andrew Kernytsky, PhD, Michael Pettiglio, Yi-Shan Chen, Kaleigh Tomkinson, Amanda Woo, Mauricio Cortes, PhD, Siyuan Tan, PhD, Todd D Borland, BS, Lawrence Klein, PhD, Angela Yen, PhD, Sudipta Mahajan, Eric Chan, PhD, Brenda Eustace, PhD, Matthew Porteus, MD PhD, Tirtha Chakraborty, PhD, Chad Cowan, Rodger Novak, MD, Ante Lundberg, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 284.
https://doi.org/10.1182/blood.V130.Suppl_1.284.284
Published: 2017
Journal Articles

Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia

Michelle I Lin, PhD, Elizabeth J Paik, PhD, Bibhu P Mishra, PhD, Song Chou, PhD, Ying Zhang, PhD, Kaleigh Tomkinson, MS, Michael A Pettiglio, BS, Andrew Sanginario, BS, Amanda Woo, BS, Min Jin Lee, BS, Melanie Allen, MS, Thomas J Cradick, PhD, Tirtha Chakraborty, PhD, Matthew Porteus, MD PhD, Ciaran M Lee, PhD, Gang Bao, PhD, Annarita Miccio, PhD, Annalisa Lattanzi, PhD, Fulvio Mavilio, PhD, Chad A Cowan, PhD, Rodger Novak, MD, Ante S Lundberg, MD
Journal: Blood
Blood (2016) 128 (22): 4708.
https://doi.org/10.1182/blood.V128.22.4708.4708
Published: 2016